Transcode Therapeutics Diluted EPS
The Diluted Earnings per Share of Transcode Therapeutics (RNAZ) as of Sep 5, 2026 is -1,319.62 USD. In the previous year, Diluted Earnings per Share was -97,611.05 USD — a change of -98.65% (higher).
Get this data via API
Financial Data API
Diluted EPS
-1,319.62USD
YoY
-98.65%
Last updated:
The Transcode Therapeutics Diluted EPS history
3 Years
10 Years
25 Years
Max
| YEAR | Diluted EPS | YoY |
|---|---|---|
| -1,319.62USD | -98.65% | |
| -97,611.05USD | -88.89% | |
| -878,250.00USD | +28.34% | |
| -684,340.00USD | +191.97% | |
| -234,390.00USD | +286.02% | |
| -60,719.99USD | +33.92% | |
| -45,340.00USD | — |
Transcode Therapeutics Stock analysis
Frequently Asked Questions about Transcode Therapeutics stock
Diluted Earnings per Share of Transcode Therapeutics is -1,319.62 USD in 2026.
Diluted Earnings per Share of Transcode Therapeutics changed from -97,611.05 USD to -1,319.62 USD, representing a -98.65% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Diluted Earnings per Share Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Income Statement — Transcode Therapeutics
All Key Metrics — Transcode Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth